Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Inhibikase Therapeutics, Inc. - Common Stock (NQ:IKT)

1.700 +0.010 (+0.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inhibikase Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Dow Surges 350 Points; US Crude Oil Stocks Increase ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Edges Lower; US Wholesale Inventories Rise 0.1% In August ↗
 
Via Benzinga
News headline image
Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today ↗
Inhibikase Therapeutics shares are trading higher by 50% during Wednesday's session. The company announced the pricing of an approximately $110 million private placement financing. 
Via Benzinga
News headline image
Dow Jumps Over 100 Points; Helen Of Troy Posts Upbeat Q2 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024 ↗
IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
Company to host conference call on August 15, 2024 at 8:00 a.m. ET 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
Company expects to report trial results in 4Q24 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024 ↗
IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023 ↗
IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate 
From Inhibikase Therapeutics
Via GlobeNewswire
News headline image
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease - 
From Inhibikase Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.